| Metric | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue | ¥13.9B | ¥7.6B | +83.2% |
| Operating Income | ¥-3.6B | ¥-14.9B | +75.6% |
| Ordinary Income | ¥-20.3B | ¥-28.4B | +28.6% |
| Net Income | ¥-20.3B | ¥-28.5B | +28.6% |
| ROE | -5.1% | -7.0% | - |
FY2026 Q1 results: Revenue ¥13.9B (YoY +¥6.3B +83.2%), Operating Income ¥-3.6B (YoY +¥11.3B +75.6% improvement), Ordinary Income ¥-20.3B (YoY +¥8.1B +28.6% improvement), Net Income ¥-20.3B (YoY +¥8.2B +28.6% improvement). Revenue increased for the second consecutive period with a substantial expansion versus the prior year; at the operating level the deficit narrowed and the profitability structure is on an improving trend. However, an equity-method investment loss of ¥16.8B weighed on ordinary income, and the bottom-line remains a large loss.
[Revenue] Revenue was ¥13.9B (YoY +83.2%), a significant increase. By segment, the Ion Exchange Membrane Business recorded ¥8.0B (YoY +193.0%), nearly triple growth and led overall expansion. The Separator Business was ¥5.9B (YoY +21.7%), a ~20% increase. Revenue mix: Ion Exchange Membrane 57.5%, Separator 42.5%, with the higher-margin Ion Exchange Membrane becoming the core.
[Profitability] Cost of goods sold was ¥15.1B, resulting in Gross Profit of ¥-1.2B (Gross Margin -9.0%), still negative but markedly improved from the prior-year gross loss of ¥-12.4B (Gross Margin -164.4%). SG&A was ¥2.4B (SG&A ratio 17.2%), contained around prior-year ¥2.5B, and Operating Income was ¥-3.6B (Operating Margin -26.3%), a 75.6% reduction in deficit from ¥-14.9B the prior year. Non-operating results included an expanded equity-method investment loss of ¥16.8B (prior year ¥13.5B), and interest expense of ¥0.7B, which heavily pressured the ordinary income level. Non-operating income amounted to only ¥1.0B (interest income ¥0.1B, foreign exchange gains ¥0.6B, etc.), and Ordinary Income was ¥-20.3B (prior year ¥-28.4B). There were no extraordinary items; after corporate taxes of ¥0.1B, Net Income was ¥-20.3B (prior year ¥-28.5B). In conclusion, while significant revenue growth and gross margin improvement reduced the operating deficit, the expansion of equity-method losses means the company continues to report a materially negative bottom-line.
The Ion Exchange Membrane Business recorded Revenue ¥8.0B (YoY +193.0%), Operating Income ¥5.2B (YoY +750.8%), and margin 65.1%, achieving a high-margin turnaround and becoming the company’s earnings driver. The Separator Business posted Revenue ¥5.9B (YoY +21.7%), Operating Loss ¥6.5B (YoY improvement +50.6%), and margin -109.5%, remaining in a substantial deficit; however, the loss narrowed by half from ¥-13.1B last year, indicating absorption of start-up costs. Profitability divergence between segments is marked, with high returns from Ion Exchange Membrane partially offsetting Separator losses.
[Profitability] Operating margin was -26.3%, improved 171.3pt from -197.6% last year but still negative; Net margin was -146.7%, improved 230.0pt from -376.7%. ROE was -5.1%, improved from -7.0%, but capital efficiency remains depressed. [Cash Quality] Interest Coverage was -5.1x (EBIT -¥3.6B ÷ Interest Expense ¥0.7B), indicating operating profits do not cover interest expense. Net Working Capital was -¥29.9B, substantially negative, creating dependence on external short-term funding. [Investment Efficiency] Total Asset Turnover was 0.11x (annualized 0.44x), low, and Investment Securities ¥337.4B account for 67.4% of total assets, restraining operating asset efficiency. Construction in Progress ¥25.0B represents 22.5% of tangible fixed assets, indicating a large CAPEX pipeline with time lag to revenueization. [Financial Soundness] Equity Ratio was 80.1%, improved from 78.7% last year, suggesting a relatively stable capital base. D/E ratio was 0.07x, maintaining low leverage; however, Current Ratio was 54.2% (Current Assets ¥35.3B ÷ Current Liabilities ¥65.2B), well below 1.0x, highlighting short-term liquidity challenges. Cash and Deposits ¥7.8B represent only 14.6% of Short-term Borrowings ¥53.4B, indicating high refinancing dependence.
Because a cash flow statement is not disclosed, funding trends are analyzed from balance sheet movements. Cash and Deposits increased from ¥2.7B to ¥7.8B, up ¥5.1B (+187.1%), improving liquidity. Short-term Borrowings decreased from ¥66.7B to ¥53.4B, down ¥13.3B, reducing short-term liabilities. Conversely, Long-term Borrowings increased from ¥11.8B to ¥21.7B, up ¥9.9B (+83.8%), showing a shift to longer-term financing. Current Assets decreased from ¥38.6B to ¥35.3B, down ¥3.3B; Inventories rose from ¥6.3B to ¥7.1B, up ¥0.8B. Fixed Assets decreased from ¥481.4B to ¥464.9B, down ¥16.5B, mainly due to Investment Securities declining from ¥346.2B to ¥337.4B (down ¥8.8B). Net Assets decreased from ¥409.3B to ¥400.8B, down ¥8.5B, reflecting the current Net Loss of ¥20.3B, although Comprehensive Income of ¥7.4B (Foreign Currency Translation Adjustment ¥2.3B, Equity-method investee OCI ¥5.0B) partially offset the decline.
Earnings quality is assessed by separating recurring operating results from one-off non-operating items. Operating loss of ¥-3.6B indicates the recurring operating earnings capacity and is an improvement from ¥-14.9B prior year but remains negative. Non-operating results include an equity-method investment loss of ¥16.8B that significantly depressed Ordinary Income; this loss depends on the performance of external investees and is structural. Non-operating income totaled ¥1.0B, or 7.2% of Revenue, limited in scale and mainly from foreign exchange gains ¥0.6B. There were no extraordinary items, indicating no temporary boosts or hits. The divergence between Operating Loss ¥-3.6B and Net Loss ¥-20.3B is large, and earnings quality is therefore driven by volatility in equity-method results. From an accrual perspective, Comprehensive Income ¥-13.0B is ¥7.3B higher than Net Income ¥-20.3B, with foreign currency translation adjustments and equity-method investee OCI totaling ¥7.3B recognized as non-cash gains.
Full Year guidance is unchanged: Revenue ¥60.0B (YoY +65.2%), Operating Income ¥-24.0B, Ordinary Income ¥-44.0B, Net Income ¥-44.0B, EPS -79.73 yen. Q1 Revenue ¥13.9B represents 23.1% of the full-year plan, slightly below a standard 25% but generally within expectations. Q1 Operating Loss ¥-3.6B corresponds to 15.0% of the full-year plan ¥-24.0B, indicating a smaller quarterly deficit. Ordinary Loss ¥-20.3B is 46.1% of the full-year plan ¥-44.0B, suggesting equity-method losses may have been concentrated in Q1. Operating-level deficits are expected to continue for the full year, but second-half improvements in Separator Business profitability and revenue expansion are anticipated; uncertainty in equity-method results remains a risk to achieving full-year guidance.
No dividends were paid; Payout Ratio is not calculable. With Net Income at a loss of ¥-20.3B there are no distributable funds. Cash and Deposits ¥7.8B are 14.6% of Short-term Borrowings ¥53.4B, indicating significant liquidity constraints. The full-year forecast anticipates Net Loss ¥-44.0B, so capital allocation will prioritize business monetization and strengthening the financial base over shareholder returns in the near term.
Continued losses in the Separator Business: The Separator Business continues to post a large operating loss of ¥6.5B (margin -109.5%) with immature cost structure relative to Revenue ¥5.9B. Although the loss narrowed by half YoY, the path to profitability remains long; if fixed cost burden and rate of utilization improvement lag expectations, it will keep pressuring consolidated earnings.
Expansion risk of equity-method investment losses: Equity-method investment losses ¥16.8B (prior year ¥13.5B) occurred at a scale exceeding operating income at the ordinary level; continued deterioration at investees would widen ordinary losses. Given Investment Securities ¥337.4B account for 67.4% of total assets, reliance on external factors increases earnings volatility and valuation uncertainty.
Liquidity risk: Current Ratio 54.2%, Cash and Deposits ¥7.8B are only 14.6% of Short-term Borrowings ¥53.4B, so short-term funding relies on rollovers. Net Working Capital -¥29.9B and Interest Coverage -5.1x indicate interest obligations are not covered by operating profits. Changes in financial conditions or reduced credit availability could trigger refinancing risk and affect business continuity.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | -26.3% | 8.8% (4.4%–14.3%) | -35.1pt |
| Net Margin | -146.7% | 7.3% (3.3%–10.6%) | -153.9pt |
Profitability is well below industry median, with both operating and net margins among the lowest in the sector.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 83.2% | 6.6% (-0.3%–14.8%) | +76.6pt |
Revenue growth substantially exceeds the industry median, placing the company among the leaders in top-line expansion.
※ Source: Company aggregation
The high-margin Ion Exchange Membrane Business is key to structural improvement, with Operating Income ¥5.2B (margin 65.1%) sharply up from ¥0.6B last year. As the core business accounting for 57.5% of Revenue, it drives earnings; monitoring sustainability of growth and price maintenance is important. The Separator Business loss narrowed from ¥-13.1B to ¥-6.5B, reflecting absorption of start-up costs, but timing of profitability remains a focal point.
Equity-method investment loss ¥16.8B significantly offset operating improvement at the ordinary level; this structure stems from Investment Securities ¥337.4B (67.4% of total assets). Disclosure of investee performance and paths to earnings improvement will determine visibility on Ordinary Income recovery. Comprehensive Income ¥-13.0B exceeds Net Income ¥-20.3B by ¥7.3B due to foreign currency translation and equity-method OCI, so caution is warranted when evaluating cash-based earnings.
Fragility in liquidity indicators (Current Ratio 54.2%, Cash/Short-term Borrowings 14.6%) represents a short-term financial risk. Long-term Borrowings increased from ¥11.8B to ¥21.7B, extending financing tenor, but sustainable financial stability cannot be secured without improved operating cash flow generation. Construction in Progress ¥25.0B (22.5% of tangible fixed assets) will lead to future asset utilization and higher depreciation; timing of commissioning and pace of revenue realization are key to judging post-FY profitability improvements.
This report is an earnings analysis document automatically generated by AI analyzing XBRL earnings filing data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company from public financial statements. Investment decisions are your own responsibility; consult professionals as needed before making investment decisions.